U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07180693) titled 'Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:' on Sept. 12.
Brief Summary: This is a multicenter observational study with both retrospective and prospective phase, designed to evaluate the clinico-pathologic characteristics and outcomes of patients with HR+/HER2- EBC at high risk of recurrence treated with ribociclib or abemaciclib in combination with ET in the adjuvant setting.
Study Start Date: Sept., 2025
Study Type: OBSERVATIONAL
Condition:
Adjuvant Therapy
CDK4/6 Inhibitor
Recruitment Status: NOT_YET_RECRUITING
Sponsor: European Institute of Oncology
Published by HT Digital Content Services...